CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model
- 14 October 2011
- journal article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 19 (1), 69-76
- https://doi.org/10.1038/cgt.2011.69
Abstract
Secondary lymphoid-tissue chemokine (SLC/CCL21) is a CC chemokine that is constitutively expressed in various lymphoid tissues and binds to chemokine receptor CCR7 on mature dendritic cells (DCs) and distinct T-and B-cell sub-populations. In vivo, CCL21 regulates the encounters between DC and T cells and thus is a key regulator of adaptive immune responses. We asked whether CCL21 is able to augment immunogenicity of a DNA-based vaccine against Her2/neu in a Balb/c mouse model with syngeneic Her2/neu+ tumor cells (D2F2/E2). Mice were vaccinated intramuscularly with plasmid DNA (pDNA) on day 1 and boosted on day 15; tumor challenge was performed subcutaneously on day 25. Coexpression of CCL21 and Her-2/neu resulted in induction of a TH1-polarized immune response and substantial improvement of the protective effect of the DNA vaccine. Coexpression of tumor antigen pDNA(Her2/neu) with both pDNA(GM-CSF) and pDNA(CCL21) as adjuvants led to further improvement of protection by the vaccine (70% tumor-free mice on day 35 vs 40% with either adjuvant alone vs 5-10% with tumor antigen alone). Our results show that CCL21 is a potent adjuvant for DNA vaccination, particularly in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). Clinical use of a pDNA(Her2/neu/CCL21/GM-CSF) vaccine might be particularly promising in minimal residual Her2/neu+ breast cancer.Keywords
This publication has 35 references indexed in Scilit:
- CCR7 is involved in the migration of neutrophils to lymph nodesBlood, 2011
- Combined Clinical Trial Results of a HER2/neu(E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Cancer Research, 2008
- Clinical utilization of chemokines to combat cancer: the double-edged swordExpert Review of Vaccines, 2007
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- CCR7 ligands stimulate the intranodal motility of T lymphocytes in vivoThe Journal of Experimental Medicine, 2007
- Intrapulmonary Administration of CCL21 Gene-Modified Dendritic Cells Reduces Tumor Burden in Spontaneous Murine Bronchoalveolar Cell CarcinomaCancer Research, 2006
- Breast cancer vaccines: a clinical reality or fairy tale?Annals of Oncology, 2005
- Cancer immunotherapy with chemoattractant peptidesSeminars in Cancer Biology, 2004
- Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor ImmunityClinical Cancer Research, 2004
- CD4+ T cell‐mediated HER‐2/neu‐specific tumor rejection in the absence of B cellsInternational Journal of Cancer, 2003